Short communication: interactions between nevirapine plasma levels, chronic hepatitis C, and the development of liver toxicity in HIV-infected patients.
Both chronic hepatitis C and nevirapine (NVP) use are risk factors for transaminase elevation under highly active antiretroviral therapy. NVP is metabolized in the liver and its clearance could be altered in the presence of chronic hepatitis C virus (HCV) infection, enhancing the risk of liver toxicity. We examined NVP plasma levels in 70 HIV-infected subjects receiving NVP-containing triple combinations. The median (range) NVP plasma trough concentrations were similar in 32 HCV antibody-positive and 38 HCV antibody-negative patients (5.8 [0.7-29] vs. 6.1 [0.9-9.6] microg/ml). Thus, HCV coinfection itself does not seem to influence significantly the pharmacokinetics of NVP in HIV-infected subjects.
Núñez
Marina
M
Department of Infectious Diseases, Instituto de Salud Carlos III, 28035 Madrid, Spain.
González-Requena
Daniel
D
González-Lahoz
Juan
J
Soriano
Vincent
V
D000410:Alanine Transaminase / Q000097:blood; D019380:Anti-HIV Agents / Q000009:adverse effects* / Q000097:blood; D000914:Antibodies, Viral; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects; D056486:Chemical and Drug Induced Liver Injury; D004347:Drug Interactions; D015658:HIV Infections / Q000097:blood / Q000150:complications* / Q000188:drug therapy; D019698:Hepatitis C, Chronic / Q000150:complications*; D006801:Humans; D008107:Liver Diseases / Q000097:blood / Q000821:virology; D019829:Nevirapine / Q000009:adverse effects* / Q000097:blood
D019380:Anti-HIV Agents; D000914:Antibodies, Viral; D019829:Nevirapine; D000410:Alanine Transaminase